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Abstract 
Smokers being witnessed with the mild adverse clinical symptoms of SARS-CoV-2, the in-
silico study is intended to explore the effect of nicotine binding to the soluble angiotensin 
converting enzyme II (ACE2) receptor with or without SARS-CoV-2 binding. Nicotine 
established a stable interaction with the conserved amino acid residues: Asp382, Gly405, 
His378 and Tyr385 through His401 of the soluble ACE2 that seals its interaction with the INS1. 
Also, nicotine binding has significantly reduced the affinity score of ACE2 with INS1 to -12.6 
kcal/mol (versus -15.7 kcal/mol without nicotine) and the interface area to 1933.6 Å2 (versus 
2057.3Å2 without nicotine). Nicotine exhibited a higher binding affinity score with ACE2-
SARS-CoV-2 complex with -6.33 kcal/mol (Vs -5.24 kcal/mol without SARS-CoV-2) and a 
lowered inhibitory contant value of 22.95 µM (Vs 151.69 µM without SARS-CoV). 
Eventhough ACE2 is not a potential receptor for nicotine binding in the healthy people, in 
COVID19 patients, it may exhibit better binding affinity with the ACE2 receptor. In overall, 
nicotine’s strong preference for ACE2-SARS-CoV-2 complex might drastically reduce the 
SARS-CoV-2 virulence by intervening the ACE2 conserved residues interaction with the spike 
(S1) protein of SARS-CoV-2.    
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Introduction  
COVID-19, a highly contagious virus strain of SARS-CoV family of Wuhan origin has become 
a major life-threat to the global population (1). Clinical studies have been widely conducted 
using various anti-viral agents; viral-protein specific monoclonal antibodies; indigenous 
therapeutic bio-actives; and convalescent plasma transfusion to attenuate the human to human 
transmission chain of COVID-19 and its virulence across the global countries (2, 3). Of all the 
clinical-therapeutic targets, including the direct COVID-19 based targets (4), the host-based 
target of angiotensin-converting enzyme 2 (ACE2) receptor has driven major attention among 
the clinical researchers for the COVID-19 management (5, 6). This is because of ACE2 acting 
as a potent agonist for COVID-19 paving its initial entry and the colonization in the upper 
respiratory system (6). ACE2 is widely expressed in the arterial-venous endothelial cells, 
including the alveolar epithelial cells of lungs, enterocytes of the small intestine and arterial 
smooth muscle cells facilitate the conversion of angiotensin-converting enzyme II to I (7, 8). 
It has been proposed that COVID-19 binding with ACE2 would affect its stability, as well as 
its biological function, resulted in increased angiotensin-II levels causing severe respiratory 
ailments on the COVID-19 patients (8, 9). Also, the increased ACE-2 expression mediated by 
the COVID-19 entry would contribute to the respiratory dysfunction by agitating the immune 
response with the increased pro-inflammatory cytokines production, especially IL-10, IL-8 and 
IL-1β (6, 10). With the ACE2 being highly expressed in lungs among the smokers than the 
healthy individuals (11), clinicians from China have found the smoking habits doesn’t 
influence the mortality rate among the smokers over the non-smokers (12). This clinical 
witness has enlightened nicotine with a bitter taste to benefit the smokers with the likely 
chances of reducing the COVID-19 virulence (12). Since the whole universe is seeking for a 
proficient clinical agent to tackle the emerging mortality of COVID-19 patients across the 
global countries, we have performed this in-silico study to evaluate the effect of nicotine on 
the soluble ACE2 receptor sensitized with the COVID-19 agonist. We find this in-silico study 
to be exciting as well as crucial because of its significance; that will unveil the clinical 
understanding of nicotine binding intervening the soluble ACE2 interactions with the crucial 
spike (S1) membrane protein of COVID-19. This computational understanding would indeed 
help the clinicians to prefer nicotine as a supplementary bio-active to treat or prevent the 
deteriorating health conditions of COVID-19 patients, especially the non-smokers, who are 
susceptible to detrimental clinical symptoms preceded by the unprecedented pro-inflammatory 
cytokines production.  
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Materials and Methods 
Homology modelling and structural characterization of human ACE2 and spike (S1) 
protein of  SARS-COV-2 (of India origin).  
Angiotensin-converting enzyme 2 (ACE2) protein sequence of Homo sapiens was obtained 
from the Uniprot database (Accession Number: Q9BYF1) (13). ACE2 is available in complete 
(aa:18-805) and soluble form (aa:18-708). They have three distinct domains viz. extracellular 
domain (aa 18-740); helical domain (aa 741-761) and a cytoplasmic domain (aa 792-805). Most 
importantly, the interface regions of ACE2 ( aa 30-41; aa 82-84 and aa 353-357) were preferred 
by S1 protein of SARS-COV-2 for protein-protein interaction. Search for a potential template 
for ACE2 from Protein Data Bank (14) listed PDB ID: 6m18 (15)  with many missing residues 
(14, 15). As a corrective measure, homology modelling was initiated using SWISS-MODEL 
online server to build the complete 3D structure of ACE2 protein (16). From the modelled 
ACE2 protein, the soluble ACE2 (sACE2) (aa region: 18-708) was derived using CHIMERA 
software for further analysis. Indian SARS-COV-2 sequence (INS1)  spike protein 
(MT012098) (17) was downloaded from NCBI and further considered for homology modelling 
using SWISS-MODEL online server. Modelled ACE2 and INS1 3D structures were energy 
minimized using CHIMERA software (18). Finally, modelled ACE2 and INS1 were chosen 
for structure validation using PROCHECK-Ramachandran plot server (19). 
 
Protein-Protein docking of soluble ACE2 with the spike (S1) membrane protein of SARS-
CoV-2  
sACE2 protein and INS1 were preferred for protein-protein docking using HADDOCK server 
(20). As per the Uniprot report, the recruited interface region was within the range of aa 30-41, 
aa 82-84 and aa 353-357 for protein-protein docking.  For INS1 protein,  the residues engaged 
with receptor interaction were scrutinized by the literature study (21, 22)  wherein the entire 
Receptor Binding Domain (aa 319-541) was chosen for the docking study. In the context of 
recruting passive residues, the checkbox was selected for ACE2 and INS1. Thus residues 
proximal to the active loci would be marked as passive residues over here. In-total about ten 
clusters of 4 poses each were generated by the HADDOCK online server. Among which the 
cluster with the least HADDOCK score was selected for the binding energy analysis using 
PDBePISA (23).  This tools helps in calculating the protein-protein interface and the overall 
binding affinity between the two proteins after docking. Docked poses and hydrogen bonds 
were examined using the Discovery Studio Visualizer (24). 
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Docking of nicotine with the homology modelled ACE2-SARS-CoV-2 complex  
Modelled ACE2 was docked with nicotine downloaded from Protein Data Bank (PDB 
ID:1UW6) (25). Here nicotine was docked with ACE2 receptor based on the study of  Joshua 
et al. wherein they have clearely mentioned that nicotine may break the interaction between 
ACE2 and SARS-COV2 (26). AutoDock Tools of version 1.5.6 was used for protein-ligand 
docking (27) (Morris, G et al, 2009). Literature evidence has shown the active site residues for 
ACE2 to be Arg273, His345, Pro346, Glu375, His505 and Tyr515 (21). Here we added 
Kollman and Gasteiger charges to the protein and ligands, respectively. The grid box was 
placed within the active site residues which are six in number. The size of the grid box was 44 
Å, 116 Å and 48Å for x, y and z, respectively. Furthermore, the grid centre was customized to 
-0.861, -6.417 and 3.778 for x, y and z, respectively. AutoGrid 4.0 and AutoDock 4.0 programs 
were used to generate the grid maps. The best ten conformers were generated using a 
Lamarckian Genetic Algorithm. Following, the sACE2-SARS-COV-2 complex was 
scrutinized for protein-ligand docking for which the grid box was generated within the sACE2 
site. The generated grid box was localized within the active site of a box size of 72Å, 44 Å and 
82Å for x, y and z, respectively. Furthermore, the grid centre was customized to 42.694, -9.11 
and 1.389 for x, y and z, respectively. Meanwhile, the AutoGrid 4.0 and AutoDock 4.0 
programs were employed to generate the grid maps. The binding energy and inhibition constant 
for each pose were calculated and the best-selected poses were marked using the Discovery 
Studio Visualizer  (24). The binding affinity and the interface are of the sACE2 protein with 
INS1 in the presence of  nicotine was calculated again using PDBePISA. 
 
Results 
Structural characteristics of the homology modelled ACE2 and the spike (S1) protein of 
SARS-CoV-2 
The downloaded ACE2 sequence was chosen for the modelling performed using SWISS-
MODEL by which the crystal structure with PDB ID: 6m18 was enlightened as a potential 
template with an amino acid identity of 100% and query coverage of 99%. The modelled 
structure comprised of both extracellular and helical domains with the amino acids ranging 
from 21 to 768. Structure validation using the Ramachandran plot has confirmed 91.4% 
residues in the favoured region; 8.2% residues in the additional allowed region; 0.4% residues 
in the generously allowed region and 0% residues in the unfavourable region. From the 
modelled structure, the soluble ACE2 structure was obtained with the amino acid residues 
ranging from 21 to 708. For INS1 protein, 6VSB was the potential template with the structural 
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homology of 99.17% and a query coverage of 95% (28). Domain details were procured from 
the literature study. The whole 3D structure model comprised of 27 to 1146 residues that got 
partitioned into S1 and S2 domain. Of the total 1146 residues, the S1 domain constitutes about 
27-541 residues, while, the S2 domain constitutes about 778-1213 residues. Further, in-detail 
classification of the INS1 protein unravels the N-terminal domain (NTD) (aa 27-305); Receptor 
Binding Domain (aa 319-436 and aa 509-541);  Receptor Binding Motif (aa 437-508); fusion 
peptide (aa 788-806); heptad repeat region ( aa 912-984); and the heptad repeat region 2 (aa 
1163-1213). These structural conformations could not be modelled because of the 
inaccessibility of its template. As per the structure validation, Ramachandran Plot test results 
revealed 86.1% residues to exist within the most favoured region; 11.9% residues in the 
additional allowed region; 11.9%; the generously allowed region was 1.7% and the disallowed 
region was 0.3%.  
 
Structural characteristics of ACE2 binding with the spike (S1) protein of SARS-CoV-2  
ACE2 was docked with the INS1 wherein the RBD of INS1 was targeted against the ACE2 
protein. Of the generated ten clusters, the one with the least HADDOCK score was considered 
for further examination. Three salt bridges were spotted with eleven hydrogen bonds with the 
ACE2-INS1 docking. Predominantly, the charged residues of ACE2 were involved in the 
interface interaction. A profound structural analysis was carried out in our previous study (29). 
The binding affinity of ACE2 with SARS-CoV-2 alone showed -15.7 kcal/mol with the 
measured interface area of 2057.3Å2 between the ACE2 and SARS-CoV-2 RBD. While upon 
nicotine interaction, the binding affinity ACE2 with SARS-CoV-2  got drastically reduced to   
-12.8 kcal/mol with the constrained interface area of 1933.6 Å2.   
 
Structural modulations inflicted by nicotine binding with the ACE2-SARS-CoV-2 protein 
complex 
With the help of localized docking approach performed using AutoDock software, nicotine was 
docked within the active site pocket of the modelled-soluble ACE2 protein (highly expressed 
in the arterio ventricular cells). Our docking results unveiled the nicotine’s ability to bind 
profoundly into the pocket of ACE2 protein (Fig. 1a). It has been found that the positively 
charged His401 is indulged in direct contact with the nicotine. Also, the His401 has established 
the concomitant interactions with the Asp382, gly405, His378 and Tyr385 residues. All these 
residues were localized in the near distal regions of the protein-protein interface (Fig. 2a). After 
docking nicotine with the ACE2-SARS-CoV-2 complex, it has been found that nicotine 
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establishes a stable interaction with Asp 368 that further interacts with the Thr362, Lys363, 
Thr365, Thr371 and Ala372 residues (Fig. 2b). All five amino acid residues engaged in these 
interactions were located at the proximal site to 353-357 segment of ACE2 protein that are 
actively participated in the stable interaction with the SARS-CoV-2 spike glycoprotein. The 
measured binding energy of nicotine with the soluble ACE2 was found to be -5.24 kcal/mol 
with the measured inhibition constant of 151.69 µM.  Contradictorily, upon the nicotine’s 
interaction with the ACE2-SARS-CoV-2 complex, its binding affinity got increased with -6.33 
kcal/mol with the reduced inhibition constant of 22.95 µM. With the nicotine being binding to 
the active pocket site of sACE2, the SARS-CoV-2 binds to the spike protein binding site of 
ACE2. However, nicotine neither established any stable interaction nor developed an inhibitory 
contant value while interacting with sACE2 receptor alone that contradicts the results shown 
above with its interaction with the sACE2-SARS-CoV-2 complex. This in-silico observation 
has vividly explained that nicotine binding could produce pronounced effects on the ACE2 
structure only while it gets sensitized with the SARS-CoV-2 binding, and not on the ACE2 
structure alone. Indeed this would clearly define the noticeable benefits of nicotine exposure 
in the COVID-19 affected patients over the unaffected healthy individuals. Moreover, with this 
steady allosteric interaction of nicotine with ACE2 receptor could profusely intervene its 
binding with the spike (S1) protein of SARS-CoV-2 thereby showing its ability to tackle the 
COVID-19 virulence at  a much lower dose on the COVID-19 patients.   
 
Discussion 
To manage the emerging COVID-19 virulence and its unprecedented transmission among the 
humans, the host-based ACE2 receptor has gathered immense attention among the clinicians 
(30). Since the COVID-19 acts as a potent agonist for ACE2 receptor (6), monoclonal 
antibodies targeting ACE2 has been proposed to be an effective treatment strategy for COVID-
19 management (31). It has been shown that COVID-19 interaction with the ACE2 receptor 
would hinder its function causing severe respiratory ailments with the increased angiotensin II 
levels (6). Based on the recent clinical evidence that witnessed only mild adverse symptoms 
on the COVID-19 patients who are habituated to smoking than their counterparts (12, 32); we 
have planned to study the effect of nicotine binding with the in-silico modelled soluble ACE2 
that is widely expressed on the arterial ventricular epithelial cells. This study is in no way tries 
to glorifiy the intake of nicotine through smoking. But it was mainly intended to understand 
the role of nicotine in inhibiting the SAR-COV2 protein from interacting with souble ACE2. 
Our docking study results have shown that nicotine has clearly established a fragile interaction 
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with the naïve soluble ACE2 receptor. Nevertheless, under the same set-up, the nicotine has 
established a stable interaction with the ACE2 receptor that got sensitized in-prior with the 
COVID-19 binding. Also, nicotine’s profound affirmative for ACE2-SARS-CoV-2 complex is 
highly likely to intervene in the interaction of ACE2 with the conserved amino acid residues 
of the spike (S1) protein of SARS-CoV-2 affecting its virulence. The study results also 
emphasize that even at a much lower concentration the nicotine would be able to hinder the 
interaction of SARS-CoV-2 with the ACE2 receptor. This might benefit the severely ill 
COVID-19 patients who are refrained from nicotine usage to overcome their adverse clinical 
symptoms by getting exposed to a much lower dose of nicotine that demands further clinical 
validation.   
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Figures 
Figure 1. sACE2 docked with Nicotine. The active site pocket of sACE2 was occupied by 
nicotine  near the SARS-COV2 binding site.  
Figure 2 sACE2  and sACE2-SARS-COV2 combo docked with nicotine (a) In sACE2 nicotine 
preferred to bind deep into the active site pocket near the SAR-COV2 binding site. But still 
they were quite away from the sACE2 protein SARS-COV2 binding site.(b) Nicotine docked 
with sACE2-SARS-COV2 docked protein which is like the disease state. Here, nicotine prefer 
to bind proximal to the spike protein binding site 
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FIGURES 
Figure 1 
 
Figure 2(a) 
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Figure 2(b) 
 
 
